SCHEMBL27217804

SCHEMBL27217804

Cc1cnc2c(N)ccc(Br)n12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 8/20 0.34
CHUK O15111 6/20 0.34
KDM4E B2RXH2 2/20 0.32
UHRF1 Q96T88 1/20 0.31
ERN1 O75460 1/20 0.31
RPS6KA4 O75676 1/20 0.31
PRKD3 O94806 1/20 0.31
CDK1 P06493 1/20 0.31
KIT P10721 1/20 0.31
CDK11B P21127 1/20 0.31
CDK2 P24941 1/20 0.31
TYK2 P29597 1/20 0.31
CSNK1D P48730 1/20 0.31
CDK7 P50613 1/20 0.31
CDK9 P50750 1/20 0.31
LIMK1 P53667 1/20 0.31
CDK16 Q00536 1/20 0.31
MAPK7 Q13164 1/20 0.31
CDK13 Q14004 1/20 0.31
PRKD1 Q15139 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1674374 0.71 IKBKB (0.36) IKBKBCHUKKDM4E
SCHEMBL2179132 0.68 IKBKB (0.34) IKBKBMAPT
SCHEMBL19510490 0.65 KDM4E (0.34) IKBKBCHUKKDM4E
Bromide SCHEMBL19510409 0.64 KDM4E (0.33) IKBKBCHUKKDM4E
SCHEMBL15061721 0.64 CYP17A1 (0.33) IKBKBCHUKKDM4E
SCHEMBL2519357 0.64 KDM4E (0.53) IKBKBCHUKKDM4EMAPT
SCHEMBL27217735 0.63 ADORA2A (0.39) KDM4EMAPT
SCHEMBL31479824 0.63 KDM4E (0.31) KDM4E
SCHEMBL21948952 0.62 ADORA2A (0.39) KDM4EAURKBMAPT
SCHEMBL23029843 0.61 KDM4E (0.38) IKBKBCHUKKDM4EERN1RPS6KA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 US disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 IKBKB 58/4885CHUK 37/4885KDM4E 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.